News

With NIH grant, Springbok Analytics takes on rotator cuff injuries

Springbok Analytics, a Charlottesville medical data company that creates 3D models from X-rays and MRIs, has received a $1.7 million government grant to develop a commercially viable algorithm that can detect and diagnose shoulder injuriesThe grant, announced Tuesday, comes from the National Science Foundation’s Small Business Innovation Research grant program. It follows a $51,409 grant the company received from the NIH in 2022 to start its R&D on the project.

Springbok will work with research partners at the University of Virginia, University of Wisconsin and the San Antonio Orthopedic Group on AI technology to provide “a more accurate and objective scoring system” for evaluating rotator cuff muscles and to gauge the prospects of patient surgeries.

Lara Riem, Springbok’s director of AI and data science, said in a statement the company created an “extensive digital database” of healthy and injured rotator cuffs through phase I of the project. She said that database helped it establish key metrics evaluating muscles that can be “derived precisely and automatically, at scale” from magnetic resonance images.

Springbok said completion of a phase II trial of the new analysis system will allow it to apply for commercial clearance from the Food and Drug Administration.

“Our ultimate goal at Springbok Analytics is to become the standard for how we understand human musculature and improve clinical diagnosis, injury management and human performance through innovative, AI-based technologies,” co-founder and Chief Science Officer Silvia Blemker said in a statement.

Springbok’s 3D MRI imaging services are used by teams across the NFL, NBA, MLB, NHL, Premier League and NCAA. Last April, it closed an oversubscribed $3 million seed round led by Transition Equity Partners that included participation from the NHL’s Chicago Blackhawks.

Read more here.

Recent News

07/01/2025

ISOThrive Announces Promising Phase 2 Interim Data for Novel Heartburn Treatment and Appoints Pharma Veteran Mike Walther as Chief Strategy Officer

ISOThrive Inc., a clinical-stage biopharmaceutical company, announced interim results from a Phase 2 study of its lead candidate, ISOT-101, for treatment of Non-Erosive Reflux Disease (NERD). The data showed positive trends in addressing heartburn frequency and symptom severity among proton pump inhibitor (PPI) partial-responders (PR), a patient population with major unmet medical need. These positive

07/01/2025

Gary Lowenthal Joins Focused Ultrasound Foundation’s Council

The Focused Ultrasound Foundation is pleased to welcome Gary Lowenthal to its Council, a dedicated group of goodwill ambassadors who work closely with the Board of Directors and staff to provide advice and assist with raising funds and building awareness. Mr. Lowenthal is a retired educator, entrepreneur, and executive with a career spanning education, international service,

06/25/2025

Liquet Medical Closes Oversubscribed Seed Round to Launch Pilot Study Evaluating Real-Time Hemodynamic Monitoring

Liquet Medical, a clinical-stage medical device company developing the Versus™ Catheter — a first-of-its-kind dual-tipped catheter system cleared by the FDA for controlled and selective infusion of fluids into the pulmonary vasculature and hemodynamic monitoring — announced the successful and oversubscribed close of its Seed funding round, which officially closed in May 2025. The capital